Skip to main content

Table 3 Number (%) of patients reporting TEAES with incidence ≥5% in any group, on-therapy period, safety population

From: A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder

 

Placebo

Desvenlafaxine

Desvenlafaxine

(n=223)

10 mg/d (n=226)

50 mg/d (n=224)

Any TEAE

147 (66)

155 (69)

154 (69)

Gastrointestinal disorders

   

  Constipation

5 (2)

4 (2)

15 (7)

  Diarrhea

11 (5)

14 (6)

17 (8)

  Dry mouth

11 (5)

17 (8)

20 (9)

  Nausea

14 (6)

21 (9)

32 (14)

General disorders

   

  Fatigue

4 (2)

7 (3)

13 (6)

Infections

   

  Upper RTI

11 (5)

18 (8)

12 (5)

Metabolism and nutrition disorders

   

  Decreased appetite

8 (4)

9 (4)

20 (9)

Nervous system disorders

   

  Dizziness

12 (5)

9 (4)

16 (7)

  Headache

17 (8)

18 (8)

16 (7)

Psychiatric disorders

   

  Insomnia

8 (4)

11 (5)

15 (7)

  1. RTI, respiratory tract infection; TEAE, treatment-emergent adverse event.